Ultragenyx Pharmaceutical Overview
Ultragenyx Pharmaceutical Target Price
Analysts' 12-month price predictions for RARE.
Share Price
$37.12
Average Target Price
$89.50
141.1% upside
141.1% upside2 analysts in the last 4 months
High: $115 | Low: $64
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-03-17 | Piper Sandler | $115 | 209.8% upside |  |
| 2025-03-07 | Morgan Stanley | $64 | 72.4% upside | |
| 2024-11-06 | H.C. WainwrightEd Arce | $95 | 155.9% upside | |
| 2024-11-06 | Leerink PartnersJoseph Schwartz | $85 | 129% upside | |
| 2024-06-06 | Goldman SachsSalveen Richter | $67 | 80.5% upside | |
| 2024-05-31 | Stifel NicolausDae Gon Ha | $127 | 242.1% upside | |
| 2024-05-31 | Raymond JamesChristopher Raymond | $135 | 263.7% upside | |
| 2024-05-31 | Robert W. BairdJoel Beatty | $72 | 94% upside | |
| 2024-05-31 | Canaccord GenuityWhitney Ijem | $111 | 199% upside | |
| 2024-04-15 | Stifel NicolausDae Gon Ha | $124 | 234.1% upside | |
| 2024-04-15 | Raymond JamesChristopher Raymond | $130 | 250.2% upside | |
| 2023-02-03 | Morgan Stanley | $95 | 155.9% upside | |
| 2022-12-30 | H.C. Wainwright | $82 | 120.9% upside | |
| 2022-07-28 | Piper SandlerChristopher Raymond | $130 | 250.2% upside | |
| 2022-07-01 | Stifel Nicolaus | $142 | 282.5% upside | |
| 2022-05-24 | Goldman Sachs | $101 | 172.1% upside | |
| 2022-05-18 | Piper SandlerChristopher Raymond | $135 | 263.7% upside | |
| 2022-05-06 | Morgan Stanley | $109 | 193.6% upside | |
| 2022-05-06 | Leerink Partners | $115 | 209.8% upside | |
| 2022-01-10 | Cowen & Co.Yaron Werber | $124 | 234.1% upside | |
| 2021-11-03 | CitigroupYigal Nochomovitz | $150 | 304.1% upside | |
| 2021-11-03 | WedbushLaura Chico | $92 | 147.8% upside | |
| 2021-09-27 | Piper SandlerChristopher Raymond | $170 | 358% upside | |
| 2021-08-19 | UBSEsther Rajavelu | $73 | 96.7% upside | |
| 2021-08-03 | BarclaysGena Wang | $141 | 279.8% upside | |